BioWorld

Feb. 17, 2005

View Archived Issues

Inverness Acquiring Ischemia In Stock Deal Worth $22.4M

Read More

Cambria Plans Parkinson's, ALS Research With Three NIH Grants

Read More

Other News To Note

Read More

FibroGen Adds Institutions In $100M Round To Boost HIF Work

Selling only about 15 percent to existing investors, privately held FibroGen Inc. placed about $100 million in convertible preferred stock to advance its pipeline in a variety of programs and start more. (BioWorld Today) Read More

Pfizer Defends Celebrex As FDA Meets On Safety Of COX-2 Class

Read More